Kaloyan Takov: Native Lp(a) Carries a Distinct Triglyceride Signature Linked to Cardiovascular Disease
Kaloyan Takov, Research Associate at Imperial College London, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Atherosclerosis, adding:
“As results emerge from the first Lp(a)-lowering outcome trials, particularly following the news that Lp(a)HORIZON did not meet its primary endpoint, it is more important than ever to look beyond Lp(a) levels alone and understand its composition.
Check out our new study in Atherosclerosis, showing that native Lp(a) carries a distinct triglyceride signature linked to incident cardiovascular disease.
These findings challenge conventional classifications and support combining better particle separation with novel technologies to capture lipoprotein heterogeneity.”
Title: Lipoprotein(a) carries triglyceride species associated with incident cardiovascular disease
Authors: Kaloyan Takov, Sider Penkov, Raimund Pechlaner, Eyad Elbahtety, Li Ern Yap, Lukas Schmidt, Sarah E. Berry, Wendy L. Hall, Bhawana Singh, Johann Willeit, Stefan Kiechl, Sotirios Tsimikas, Stefan R. Bornstein, Maria Fedorova, Manuel Mayr
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC